60 results about "Release factor" patented technology

This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.

The invention discloses an automatic sleep staging method of a single-lead electroencephalogram. A training model comprises a feature extraction module and a staging optimization module, the feature extraction module comprises CNNs (convolutional neural networks) (1) and an Softmax layer (2), the staging optimization module comprises bi-directional LSTM (long-short term memory) recurrent neural networks (3) and a CRF (corticotropin releasing factor) conditional random field model (4), and the CNNs (1), the Softmax layer (2), the LSTM recurrent neural networks (3) and the CRF conditional random field model (4) are sequentially connected. The method only needs the single-lead sleep electroencephalogram, portable and comfortable sleep monitoring requirements are met, temporal and spatial characteristics of the electroencephalogram are sufficiently excavated according to the convolutional neural networks and the recurrent neural networks, the method has dynamic learning capacity and can adapt to great changed environments of diseases, the staging optimization module sufficiently considers relation between the front and the back of N 30s of electroencephalogram data, and the staging accuracy and the generalization ability of the model are improved.

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

The invention relates to genomically recoded organisms, platforms for preparing sequence defined biopolymers in vitro comprising a cellular extract from a genomically recorded organism, and methods for preparing sequence defined biopolymers in vitro are described. In particular, the invention relates to genomically recoded organisms comprising a strain deficient in release factor 1 (RF-1) or a genetic homolog thereof and at least one of at least one additional genetic knock-out mutation, at least one additional upregulated gene product, or both at least one additional knock-out mutation and at least one additional upregulated gene product.

The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of Salmonella bacteria containing nucleic acid expression constructs encoding shRNAs. In this process, shRNA expressed by the Salmonella silences or knocks down genes of interest (target genes) inside target cells. The nucleic acid expression constructs of the invention include an RNA polymerase (e.g., a T7 polymerase), an RNA polymerase promoter (e.g., a T7 polymerase promoter), and an RNA polymerase terminator (e.g., a T7 polymerase terminator). The Salmonella bacteria can also include, on the same or different nucleic acid construct, an endosomal release factor (e.g., HlyA).

Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

The present invention relates to process of extracting growth hormone release factor (GHRF) from pilose antler. The process includes the following steps: 1. crushing pilose antler and leaching to obtain leached liquid; 2. ultrafiltering the leached liquid and collecting the pilose antler extract of molecular weight 1-10 kDa; and 3. high efficiency liquid chromatography on the pilose antler extract and collecting component containing GHRF of pilose antler. The present invention also relates to the pilose antler extract with rich GHRF, and its application in medicine, food, cosmetics, feed, etc.

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Provided are probes comprising a class 1 release factor conjugated to a fluorescent label and methods of making the probes. Also provided are methods for detecting conformational changes in ribosomes and associated molecules, such as class 1 release factors. In addition, methods of identifying a compound for reducing nonsense-mediated decay of mRNA and / or for inhibiting termination of protein synthesis at a premature stop codon, are described. Methods of assaying RF3 activity are also included.

The invention belongs to the technical field of medicine compositions, and discloses an external use medicine composition used for treating alopecia. The external use medicine composition comprises annular adrenocorticotrophic hormone release factor (CRF) antagonism peptide astressin B in effective treatment amount or acceptable salt on the pharmacy. The external use medicine composition is in a gel dosage form preferably and suitable for clinic use and industrialization production. In addition, the invention further discloses a method for preparing the external use medicine composition and application of the astressin B in effective treatment amount or the acceptable salt on the pharmacy to preparing the external use medicine composition used for treating the alopecia. According to the external use medicine composition, the problem of the alopecia for a long time can be effectively treated; and the external use medicine composition is safe, reliable, free of obvious skin irritants and free of sensitization.

The present invention relates to processes for the production of α-aryl-β-ketonitriles, which serve as synthetic intermediates in the preparation of a series of biologically important molecules such as corticotropin releasing factor (CRF) receptor antagonists.

In some aspects, the invention relates to methods for increasing insulin-sensitivity and / or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the invention may be use to treat a variety of metabolic diseases such as type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity.

Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.

In some aspects, the invention relates to methods for increasing insulin-sensitivity and / or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the invention may be use to treat a variety of metabolic diseases such as type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity.

The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

A method for treating or preventing a host mammal that exhibits aversive signs and symptoms present during protracted abstinence or extended discontinuation syndromes as seen after cessation of compulsive activity, behaviors, or substance use is disclosed. That method comprises administering to a host mammal in need a pharmaceutical composition containing an aversive sign and symptom lessening amount a compound of Formula I or a pharmaceutically acceptable salt thereof dissolved or dispersed in a physiologically acceptable diluent, and repeating the administration as needed,wherein W, X, Y and Z, R1 and Ar are defined within. Data are provided in rats as host mammals using behavioral models dependent on the CRF1 system: defensive burying, alcohol dependence, cocaine dependence and nicotine dependence. A contemplated method also is useful for inhibiting relapse of such a behavior. A contemplated method also is useful for treating substance-related or substance-induced psychiatric disorders that include aversive signs and symptoms.

The invention discloses a calf beef producing property improving method, which comprises the following steps: 1) injecting expressive plasmid of growth hormone releasing factor gene in the calf musculus semitendinosus positing, 2) setting the fitful agent quantity at 5-7mg per calf, 3) adopting the density of injection dilution liquid of expressive plasmid at 0.25% bupivacaine PSS, 4) improving beef producing property without influencing quality and safety.

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction pathways, increase CRF2R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF2R agonists, antibodies to CRF2R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF2R as the target for intervention and methods for treatment of muscular dystrophies are described.

The invention relates to a method for expressing recombinant protein containing unnatural amino acid in animal cells, which comprises the following steps: on the basis of four groups of aminoacyl-tRNA synthetases and corresponding tRNA, constructing aminoacyl-tRNA for identifying termination codons, and screening to obtain three gene codon expansion systems. The three gene codon expansion systems are high in termination codon reading efficiency and high in mutual compatibility, so that three non-natural amino acids can be inserted into one foreign protein, or different non-natural amino acids can be inserted into three foreign proteins of the same cell respectively. In order to further improve the readthrough rate, the release factor eRF1 is mutated to weaken the interaction between the release factor eRF1 and the termination codon.

Analysis of a goat serum product with many therapeutic effects is described. The product is identified as containing proopiomelanocortin (POMC) and Corticotropin releasing factor (CRF) peptides, as well as breakdown products of these peptides. We describe methods of treatment of diseases including cancers, multiple sclerosis, and neural disorders using these peptides and their products, as well as medicaments including such peptides and methods of producing the peptides.

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I);and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of Salmonella bacteria containing nucleic acid expression constructs encoding shRNAs. In this process, shRNA expressed by the Salmonella silences or knocks down genes of interest (target genes) inside target cells. The nucleic acid expression constructs of the invention include an RNA polymerase (e.g., a T7 polymerase), an RNA polymerase promoter (e.g., a T7 polymerase promoter), and an RNA polymerase terminator (e.g., a T7 polymerase terminator). The Salmonella bacteria can also include, on the same or different nucleic acid construct, an endosomal release factor (e.g., HlyA).

Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.